|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1994-2-25
|
|
pubmed:abstractText |
Chemotherapy-induced emesis is one of the most disturbing side effects in cancer therapy. Thus, antiemetic treatment is a mandatory adjunct in emetogenic chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
445-54
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8293412-Adult,
pubmed-meshheading:8293412-Aged,
pubmed-meshheading:8293412-Aged, 80 and over,
pubmed-meshheading:8293412-Antiemetics,
pubmed-meshheading:8293412-Cisplatin,
pubmed-meshheading:8293412-Female,
pubmed-meshheading:8293412-Humans,
pubmed-meshheading:8293412-Indoles,
pubmed-meshheading:8293412-Male,
pubmed-meshheading:8293412-Metoclopramide,
pubmed-meshheading:8293412-Middle Aged,
pubmed-meshheading:8293412-Nausea,
pubmed-meshheading:8293412-Neoplasms,
pubmed-meshheading:8293412-Quality of Life,
pubmed-meshheading:8293412-Vomiting
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
|
|
pubmed:affiliation |
Department of Gynecologic Oncology, Orebro Medical Center Hospital, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
